GenSight Biologics SIGHT.PA (EURONEXT) Mar 2026: shares €0.09, LUMEVOQ readouts
GenSight Biologics (SIGHT.PA) closed the session on 23 Mar 2026 with investors focused on clinical milestones. SIGHT.PA stock finished near €0.0851 as the company released results and guided attention to upcoming LUMEVOQ and GS030 trial updates. Market closed trading left volume at 556,065 shares, highlighting investor caution ahead of clinical catalysts.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
